What question did this study set out to answer?

The study aims to describe the timelines for initiating lecanemab treatment based on pretreatment diagnostics in Japan.

April 23, 2026Journal of Alzheimer s Disease0 citations

Early adoption of lecanemab in Japan (December 2023–December 2024): Pretreatment diagnostic timelines from the DeSC claims database

SNSaki Nakashima KSKenichiro Sato YNYoshiki Niimi

Key Points

The study aims to describe the timelines for initiating lecanemab treatment based on pretreatment diagnostics in Japan.
Utilized the DeSC claims database to analyze patient data.
Identified timelines from cognitive assessments, MRI, PET, and CSF sampling to treatment initiation.
Involved a cohort of 76 patients from 45 institutions.
Mean time to first lecanemab infusion was 103.9 days from cognitive assessment.
Infusion occurred 30.9 days after PET and 85.8 days after CSF sampling.
Longer post-test intervals were observed after CSF sampling (Bonferroni-adjusted p = 0.015).

Abstract

Using the Japanese DeSC claims database, we described pretreatment timelines for lecanemab initiation during early rollout (December 2023–December 2024). We identified 76 patients (mean age 74.6 years; 34.2% men) from 45 institutions. Mean time to first infusion was 103.9 days from cognitive assessment and 63.1 days from MRI. PET-to-infusion was 30.9 days, whereas cerebrospinal fluid (CSF) sampling-to-infusion was 85.8 days; the post-test interval remained longer after CSF (Bonferroni-adjusted p = 0.015). Although this claims-based snapshot may not represent all practice in Japan, it suggests that the CSF-based pathway can be associated with a longer post-test interval before treatment initiation.

问 AI

Bookmark

View Full Paper